Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer
Language English Country Greece Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
21508401
PII: 31/4/1447
Knihovny.cz E-resources
- MeSH
- CA-19-9 Antigen blood MeSH
- Antigens, Neoplasm blood MeSH
- Early Diagnosis MeSH
- Diagnosis, Differential MeSH
- Carcinoembryonic Antigen blood MeSH
- Keratin-19 blood MeSH
- Cohort Studies MeSH
- Humans MeSH
- Biomarkers, Tumor blood MeSH
- Liver Neoplasms blood diagnosis secondary MeSH
- Breast Neoplasms blood diagnosis MeSH
- Prognosis MeSH
- Breast metabolism MeSH
- Retrospective Studies MeSH
- Case-Control Studies MeSH
- Thymidine Kinase blood MeSH
- Tissue Polypeptide Antigen blood MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- CA-19-9 Antigen MeSH
- antigen CYFRA21.1 MeSH Browser
- Antigens, Neoplasm MeSH
- Carcinoembryonic Antigen MeSH
- Keratin-19 MeSH
- Biomarkers, Tumor MeSH
- Thymidine Kinase MeSH
- Tissue Polypeptide Antigen MeSH
AIM: The liver is the site of breast cancer metastasis in 50% of patients with advanced disease. Tumour markers have been demonstrated as being useful in follow-up of patients with breast cancer, in early detection of recurrence of breast cancer after radical surgical treatments, and in assessing oncologic therapy effect, but no study has been carried out on their usefullness in distinguishing benign liver lesions from breast cancer metastases. The aim of this study was therefore to evaluate the importance of tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen CA19-9 (CA19-9), thymidine kinase (TK), tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and cytokeratin 19 fragment (CYFRA 21-1) in differential diagnosis between benign liver lesions and liver metastases of breast cancer. PATIENTS AND METHODS: The study includes 3 groups: 22 patients with liver metastases of breast cancer; 39 patients with benign liver lesions (hemangioma, focal nodular hyperplasia, liver cyst, hepatocellular adenoma); and 21 patients without any liver disease or lesion that were operated on for benign extrahepatic diseases (groin hernia, varices of lower limbs) as a control group. The serum levels of tumour markers were assessed by means of immunoanalytical methods. RESULTS: Preoperative serum levels of CYFRA 21-1, TPA, TPS and CEA were significantly higher in patients with liver metastases of breast cancer in contrast to healthy controls and patients with benign liver lesions (p-value<0.05). Serum levels of CA19-9 and TK were higher in patients with malignancy in comparison with benign liver disease and healthy controls but these differences were not statistically significant. CONCLUSION: Tumour markers CEA, CYFRA 21-1, TPA and TPS can be recommended as a good tool for differential diagnosis between liver metastases of breast cancer and benign liver lesions.
